A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Launched by SUZHOU SUNCADIA BIOPHARMACEUTICALS CO., LTD. · Jun 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SHR-2017 Injection to see if it can help prevent bone problems in people who have cancer that has spread to their bones from other parts of the body. The goal is to find out how well this medicine works and how safe it is, as well as to determine the best dose for treating these bone issues.

People who might be eligible for this study are adults aged 18 or older who have a confirmed diagnosis of solid tumors (like breast, lung, or prostate cancer) that have spread to the bones. Participants need to be generally well enough, with a good level of daily functioning, and expected to live at least six more months. Women must not be pregnant or breastfeeding. If someone has had certain surgeries, ongoing infections, brain metastases, or heart problems, they may not be able to join. In the trial, participants will receive the SHR-2017 Injection, and the researchers will carefully watch for any benefits or side effects. This study has not started recruiting yet, so people interested should keep an eye out for when enrollment begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Able and willing to provide a written informed consent；
• • 2. Male or female, ≥18 years of age；
• • 3. Histologically or cytologically confirmed solid tumors；
• • 4. At least 1 bone metastasis demonstrated by radiologic imaging or histopathology；
• • 5. Eastern Cooperative Oncology Group performance Status≤2。
• • 6. Life expectancy was judged by the investigators to be at least 6 months;
• • 7. Adequate organ function at Screening
• • 8. Female subjects with a negative blood pregnancy test and are not breastfeeding
• Exclusion Criteria:
• • 1. Pre-existing or comorbid related oral diseases or oral cavity requiring surgery, etc；
• • 2. History of major joint (e.g., hip, knee, or shoulder) trauma or surgery prior to the first dose of the drug；
• • 3. Received radiotherapeutic drugs or bone radiotherapy prior to the first study drug administration
• • 4. Any cardiovascular disease for which the investigator considers the subject unfit to participate in the study
• • 5. resting tachycardia or resting bradycardia;
• • 6. The subject's pain is predominantly from pain unrelated to the bone metastases;
• • 7. Subject is unable to perform a pain assessment;
• • 8. Symptomatic or treatment-requiring brain metastases or other central nervous system metastases
• • 9. Comorbid infectious disease
• • 10. Prior receipt of exogenous nerve growth factor or anti-nerve growth factor antibodies;
• • 11. Prior history of allergy to relevant drug ingredients or components;
• • 12. Participation in other clinical trials within a certain period of time
• • 13. Subjects who, in the opinion of the investigator, have any other factors